RTI Biologics (RTIX) Cuts FY10 Outlook
Tweet Send to a FriendGet Alerts RTIX Hot Sheet
Price: $4.06 -1.22%
Revenue Growth %: -7.6%
Financial Fact:
Income tax provision: 400K
Today's EPS Names:
ANF, DXLG, FL, More
Revenue Growth %: -7.6%
Financial Fact:
Income tax provision: 400K
Today's EPS Names:
ANF, DXLG, FL, More
Trade RTIX Now!
RTI Biologics (Nasdaq: RTIX) lowers its FY10 EPS guidance from 15-17c to 10-12c and its sales guidance from $174.5-$177.5 million to $165-$168 million. The Street is currently looking for EPS of 11c on sales of $168.09 million.
The guidance comes amid a distribution pact with Zimmer Dental.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The guidance comes amid a distribution pact with Zimmer Dental.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Abercrombie & Fitch Co. (ANF) Misses Q1 EPS by 4c; Guides FY Below Views
- Kirkland's, Inc. (KIRK) Tops Q1 EPS by 5c; Guides FY13 EPS
- Pandora (P) Pops Higher on Q1 Results; Expands Listener Base by 2.5M Subs
Create E-mail Alert Related Categories
Corporate News, Guidance
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
